Merck fails to secure expanded indications for two cardiovascular products
This article was originally published in Scrip
Executive Summary
The US FDA has declined to approve a new indication for two Merck & Co products, Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe), because the study submitted to the agency did not assess the independent contributions of the individual drugs towards the efficacy result.